tirzepatide and blood pressure New Study Finds Use Lowered in Patients with Obesity Effects of tirzepatide, a dual

Easy-to-read information on each side of the box

### Funding Statement SDL and AC were supported by the National Science Foundation (Grant Nos.\ CAREER DMS-1944574 and DMS-2325258) ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained

When they stop, the behaviors and risks that led them there often return

PlexusDx offers compounded semaglutide therapy tailored to your metabolic needs, with personalized genetic insights to optimize your treatment plan

In a pre-specified secondary analysis of the SELECT trial, once-weekly subcutaneous semaglutide 2.4mg in patients with obesity was associated with a 22% reduction in the main 5-component kidney composite endpoint compared to patients on placebo.